SELLAS Life Sciences Group, Inc. (SLS)
Company Description
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States.
The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials.
The company is headquartered in New York, New York.
Country | United States |
Founded | 2012 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 17 |
CEO | Dr. Angelos M. Stergiou M.D., ScD h.c. |
Contact Details
Address: 7 Times Square, Suite 2503 New York, New York 10036 United States | |
Phone | (646) 200-5278 |
Website | sellaslifesciences.com |
Stock Details
Ticker Symbol | SLS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001390478 |
CUSIP Number | 81642T209 |
ISIN Number | US81642T2096 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Angelos M. Stergiou M.D., ScD h.c. | Founder, President, Chief Executive Officer and Director |
John Thomas Burns CPA | Senior Vice President and Chief Financial Officer |
Stacy E. Yeung | Vice President, Associate General Counsel and Head of Compliance |
Dr. Dragan Cicic M.D., MBA | Senior Vice President of Clinical Development |
Andrew Elnatan | Vice President and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls and Quality |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 28, 2024 | 8-K | Current Report |
Mar 18, 2024 | 424B5 | Filing |
Mar 15, 2024 | 8-K | Current Report |
Mar 11, 2024 | 8-K | Current Report |
Mar 8, 2024 | 8-K | Current Report |
Mar 5, 2024 | 8-K | Current Report |
Feb 16, 2024 | 8-K | Current Report |
Feb 7, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Jan 19, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Jan 8, 2024 | 8-K | Current Report |